Introduction & Objective: Chronic kidney disease (CKD) represents a significant complication in patients with type 2 diabetes (T2D), leading to increased morbidity and mortality. SGLT2 inhibitors (SGLT2i) have shown promise for improving renal outcomes. This prospective observational study (NCT05047471) aimed to evaluate the influence of SGLT2i, alone or in combination with other antidiabetic agents, on the progression of renal dysfunction.

Methods: Rate ratios and their confidence intervals were used to evaluate the results.

Results: A total of 9,672 patients with T2D were evaluated at baseline at 45 hospitals, with 6,707 reaching the 26-week endpoint. The SGLT2i group showed a significantly higher HbA1c improvement rate compared to the non-SGLT2i group with a rate ratio (RR) of 1.09 (95% CI 1.03-1.15). In addition, the SGLT2i group showed a significantly lower risk of eGFR decrease (RR 0.83, 95% CI 0.78-0.87) and urinary albuminine ratio increase (RR 0.93, 95% CI 0.88-0.98). The combined endpoint of HbA1c reduction with stable renal function showed a significantly higher RR in the SGLT2i group at 1.17 (95% CI 1.11-1.23) compared to the non-SGLT2i group. Various hierarchical and results can be found in Figure 1.

Conclusion: These results highlight the potential benefits of SGLT2i in the treatment of CKD and support consideration of these agents in the treatment of patients with T2D and renal complications.

graphic
View largeDownload slide
Disclosure

Y. Xue: None. L. Shi: None. X. Yu: None. Y. Wang: None. T. Hong: None. X. Li: None. J. Ma: None. D. Zhu: None. Y. Mu: None.

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.